SEC Form 4/A · accession 0001140361-15-004197
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
This is an amendment (Form 4/A). It replaces an earlier filing for the same period.
Reporting owner
John A. Lewicki
Officer — EVP & Chief Scientific Officer
Period of report
Feb 2, 2015
Accepted (ET)
Feb 4, 2015 · 7:26 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2,F3 | $1.43 | Feb 2, 2015 | M | 4,000 | A | — | Jan 11, 2017 | Common Stock | 4,000 | 40,277 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on May 13, 2014.
- F2The option is fully vested and exercisable, subject to an annual limitation of 175,438 shares that can be issued to a single grantee upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan.
- F3This amendment is filed solely to correct the expiration date reported for the option. All other information on the original Form 4 filing remains unchanged.